Evaluating systematic reviews in urology: A practical guide

Indian Journal of Urology

Volumn 23, Issue 3, 2007, Pages 224-233

  Tharyan, Prathap ^a  

^a CHRISTIAN MEDICAL COLLEGE   (India)

Author keywords

Meta analysis; Systematic review

Indexed keywords

EID: 34547844223     PISSN: 09701591     EISSN: None     Source Type: Journal    
DOI: 10.4103/0970-1591.33441     Document Type: Review

References (32)

1. Sackett D. Evidence-based medicine: How to practice and teach EBM. Churchill Livingstone: New York; 2000.
2. Concato J, Shah N, Horwitz RI. Randomized, controlled trials, observational studies, and the hierarchy of research designs. N Engl J Med 2000;342:1887-92.
3. Pai M, McCulloch M, Gorman JD, Pai N, Enanoria W, Kennedy G, et al. Systematic reviews and meta-analyses: An illustrated, step-by-step guide. Natl Med J India 2004;17:86-95.
4. Mulrow CD. Rationale for systematic reviews. BMJ 1994;309:597-9.
5. Jüni P, Altman DG, Egger M. Systematic reviews in health care: Assessing the quality of controlled clinical trials. BMJ 2001;323:42-6.
6. Tharyan P. The Cochrane Schizophrenia Group: Preparing, maintaining and disseminating the evidence for interventions used for people with schizophrenia. Int Rev Psychiatry 2005;17:115-21.
7. Evans D. Hierarchy of evidence: A framework for ranking evidence evaluating healthcare interventions. J Clin Nurs 2003;12:77-84.
8. Jadad AR, Cook DJ, Jones A, Klassen TP, Tugwell P, Moher M, et al. Methodology and reports of systematic reviews and meta-analyses: A comparison of Cochrane reviews with articles published in paper-based journals. JAMA 1998;280:278-80.
9. Jørgensen AW, Hilden J, Gøtzsche PC. Cochrane reviews compared with industry supported meta-analyses and other meta-analyses of the same drugs: Systematic review. BMJ 2006;333:782-7.
10. Moehrer B, Hextall A, Jackson S. Oestrogens for urinary incontinence in women. Cochrane Database Syst Rev 2003:CD001405.
11. Wheeler DM, Vimalachandra D, Hodson EM, Smith GH, Craig JC. Interventions for primary vesicoureteric reflux. Cochrane Database Syst Rev 2004:CD001532.
12. Advanced Bladder Cancer (ABC) Meta-analysis Collaboration. Adjuvant chemotherapy for invasive bladder cancer (individual patient data). Cochrane Database Syst Rev 2006:CD006018.
13. Ilic D, O'Connor D, Green S, Wilt T. Screening for prostate cancer. Cochrane Database Syst Rev 2006:CD004720.
14. Wilt T, Ishani A, Mac Donald R. Serenoa repens for benign prostatic hyperplasia. Cochrane Database Syst Rev 2002:CD001423.
15. Bent S, Kane C, Shinohara K, Neuhaus J, Hudes ES, Goldberg H, et al. Saw palmetto for benign prostatic hyperplasia. N Engl J Med 2006;354:557-66.
16. Berner MM, Hagen M, Kriston L. Management of sexual dysfunction due to antipsychotic drug therapy. Cochrane Database Syst Rev 2007:CD003546.
17. Moher D, Cook DJ, Eastwood S, Olkin I, Rennie D, Stroup DF. Improving the quality of reports of meta-analyses of randomised controlled trials: The QUOROM statement. Quality of Reporting of Meta-analyses. Lancet 1999;354:1896-900.
18. Higgins JP, Green S, editors. Cochrane handbook for systematic reviews of interventions 4.2.5 [updated May 2005]. In : The Cochrane Library, Issue 3. John Wiley and Sons Ltd: Chichester, UK; 2005.
19. Richardson WS, Wilson MC, Nishikawa J, Hayward RS. The well-built clinical question: A key to evidence-based decisions. ACP J Club 1995;123:A12-3.
20. Schulz KF, Chalmers I, Hayes RJ, Altman D. Empirical evidence of bias. Dimensions of methodological quality associated with estimates of treatment effects in controlled clinical trials. JAMA 1995;273:408-12.
21. Dickersin K. The existence of publication bias and risk factors for its occurrence. JAMA 1990;263:1385-9.
22. Felson DT. Bias in meta-analytic research. J Clin Epidemol 1992;45:885-92.
23. Suarez-Almazor ME, Belseck E, Homik J, Dorgan M, Ramos-Remus C. Identifying clinical trials in the medical literature with electronic databases: MEDLINE alone is not enough. Control Clin Trials 2000;21:476-87.
24. Moher D, Pham B, Jones A, Cook DJ, Jadad AR, Moher M, et al. Does the quality of reports of randomized trials affect estimates of intervention efficacy reported in meta-analyses? Lancet 1998;352:609-13.
25. Jadad AR. Randomized controlled trials: A user's guide. BMJ Books: London; 1998.
26. Devereaux PJ, Manns BJ, Ghali WA, Quan H, Lacchetti C, Moutori VM, et al. Physician interpretations and textbook definitions of blinding terminology in randomized controlled trials. JAMA 2001;285:20003.
27. Begg CB, Cho MK, Eastwood S, Horton R, Moher D, Olkin I, et al. Improving the quality of reporting of randomized controlled trials: The CONSORT statement. JAMA 1996;276:637-9.
28. Altman DG, Schulz KF, Moher D, Egger M, Davidoff F, Elbourne D, et al. The revised CONSORT statement for reporting randomized trials: Explanation and elaboration. Ann Intern Med 2001;134:663-94.
29. Altman DG. Endorsement of the CONSORT statement by high impact medical journals: Survey of instructions for authors. BMJ 2005;330:1056-7.
30. Hewitt C, Hahn S, Torgerson DJ, Watson J, Bland JM. Adequacy and reporting of allocation concealment: Review of recent trials published in four general medical journals. BMJ 2005;330:1057-8
31. Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ 2003;327:557-60.
32. LeLorier J, Gregoire G, Benhaddad A, Lapierre J, Derderian F. Discrepancies between meta-analyses and subsequent large randomized, controlled trials. N Engl J Med 1997;337:536-42.